NCT02234999

Radiolabeled Study of CC-122 in Healthy Subjects

A Phase 1, Single-center, Open-label Study to Evaluate the Metabolism and Excretion of [14C]-CC-122 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: Celgene · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To evaluate the metabolism and excretion of \[14C\]-CC-122 in healthy male subjects

Detailed description

This is a single-center, open-label study to evaluate the metabolism and excretion of \[14C\]-CC-122 following a single oral dose of \[14C\]-CC-122 in healthy male subjects. It is planned for 6 subjects to be enrolled; each subject will participate in a screening phase, a baseline phase, a treatment phase, and a follow up phone call. Blood, urine and fecal samples will be collected for analyses.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	CC-122	3mg \[14C\]-CC-122 will be administered as a single dose

Timeline

• Start date: 2014-09-23
• Primary completion: 2014-10-08
• Completion: 2014-10-08
• First posted: 2014-09-09
• Last updated: 2019-11-12

Locations

1 site across 1 country: United States